Pulmonary surfactant is a lipoprotein complex responsible for preventing the collapse of alveoli and increasing lung compliance.Therapeutically, exogenous surfactant administration, or surfactant replacement therapy(SRT), is considered in preterm infants with radiographic (small volume lungs, haziness/ ground-glass appearance, air bronchograms, and loss of cardiac borders on chest radiographs) and clinical evidence of neonatal respiratory distress syndrome (NRDS). Surfactant administration in preterm infants with NRDS reduces morbidity and mortality. There is a reduced risk of air leak and chronic lung disease. In NRDS, the earlier surfactant is used, the better the outcomes. Also, the outcome is reportedly better, if early surfactant administration is followed by extubation of preterm infants with RDS as compared to prolonged ventilation after surfactant administration.
Therapeutically, surfactant administration is also indicated in infants who have meconium aspiration syndrome. Surfactant use, in this case, will recover oxygenation and reduce the need for extracorporeal membrane oxygenation (ECMO). Also, infants who undergo intubation for any reason, irrespective of their gestational age or infants who have respiratory failure requiring mechanical ventilation, can receive surfactant therapy.
Prophylactic use of surfactant is indicated in the neonates who are predisposed to the development of NRDS. These include those who are born before 32 weeks gestation and those with low birth weights (less than 1300 gm). In premature infants, at risk for developing RDS, the surfactant administration with brief lung-protective ventilation (followed by extubation to nasal CPAP) has been found to lower incidence of mechanical ventilation, air leak syndromes, and result in a lower incidence of pneumothorax, pulmonary interstitial emphysema and improved survival without bronchopulmonary dysplasia. Prophylactic surfactant is also indicated in infants with laboratory evidence of surfactant deficiency (lecithin/sphingomyelin ratio of less than 2 to 1, evidence of lung immaturity on bubble stability test or absence of phosphatidylglycerol). Surfactant replacement therapy may also be a consideration in other situations like worsening pulmonary hemorrhage.
The use of surfactant may also be beneficial in case of severe respiratory syncytial virus-induced respiratory failure. In this case, there may be an improvement in gas exchange and respiration, contributing to shortened hospital stay and duration of mechanical ventilation.
As mentioned above, pulmonary surfactant is a lipoprotein. Its production begins around 26 weeks gestation and reaches mature levels at approximately 35 weeks. It is produced in the endoplasmic reticulum (ER) of type two pneumocytes and secreted from the lamellar bodies of type two pneumocytes. Other cells in the lung, namely club or Clara cells, also produce surfactant. This lipoprotein mixture enhances lung compliance and aids in lowering the surface tension of the air-liquid interface within alveolar walls, which will ultimately prevent atelectasis.
A large portion of the composition of surfactant is phospholipid dipalmitoylphosphatidylcholine (DPPC), which makes up about 50% of its structure. Phosphatidylglycerol is the second most abundant phospholipid in the structure. Other lipid constituents of surfactant include neutral lipids such as cholesterol and other phospholipids such as sphingomyelin (SM). Surfactant proteins comprise about 10% of the structure and interact extensively with phospholipids. They are SP-A, SP-B, SP-C, and SP-D. The SP-A and SP-D proteins are part of the innate immune response. These proteins coat bacteria and viruses, allowing phagocytosis and destruction by macrophages. SP-A also appears to be a part of a negative feedback mechanism that controls the release of surfactant from type II alveolar cells. SP-B and SP-C are hydrophobic proteins that control the rate at which surfactant covers the surface of alveoli.
The American Academy of Pediatrics 2014 guidelines recommend immediate management of all preterm infants with nasal continuous positive airway pressure. Subsequently, in selected patients, surfactant administration may be considered as an alternative to intubation with prophylactic or early surfactant administration. Surfactant replacement therapy is administered by trained personnel in a clinical setting where equipment for intubation and resuscitation are readily available.
The endotracheal instillation of surfactant is the most widely accepted technique. Surfactant is administered in liquid form via an endotracheal tube in a single bolus dose as quickly as the neonate tolerates. Some studies recommend the administration of all the surfactant at once while others advocate dividing the bolus into smaller aliquots.
Another technique of administration known as the INSURE technique is approached with the neonate not already intubated. The INSURE technique uses an in-out intubation procedure to administer the surfactant. This process includes intubation, followed by administration of the drug, and then extubation. Newer methods to limit the invasiveness of older approaches are in practice and targets of research today. One such technique is known as the Minimally Invasive Surfactant Therapy or MIST. The MIST method connects the patient to non-invasive respiratory support, and through that, the surfactant administration is with the work of spontaneous breathing. This method is increasingly used to reduce intubation rates and their associated pathologies. Another method is the less invasive surfactant administration or LISA technique. This method utilizes a thin catheter for surfactant delivery, which serves to reduce the possibility of lung injury, as is possible with intubation. At present, five surfactants (lucinactant, colfosceril palmitate, beractant, calefacient, and protectant alfa) have FDA approval. Colfosceril palmitate is no longer commercially available. Lucinactant is the first U.S. FDA-approved protein-containing synthetic surfactant.
The usage of surfactant can lead to bradycardia and hypotension in the neonate. There are also some reports of instances of oxygen desaturation upon administration of the drug. Also, because conventional methods of surfactant administration require an endotracheal tube, certain risks are associated with tubal administration of any drug. Hygiene is of vital importance, especially in neonates, as their immunities are underdeveloped. Infections and sepsis can occur if there are no measures taken to prevent them. Unless the neonate is already intubated, intubation must take place first, which presents with the risk of injury and air leaks. Intubation also poses the risk of airway obstruction, mechanical damage to the airway, and it may require frequent suctioning. There is a risk of alterations in cerebral flow and hypoxemia. Concomitant administration of oxygen can damage lung tissue from oxygen pressure. Excess oxygenation and subsequent cessation of it leads to diseases like bronchopulmonary dysplasia and retrolental fibroplasia in infants as well.
Since surfactant extraction is from animal sources, a risk of immune activation exists. Rarely the drug can lead to pneumothorax and/or pulmonary hemorrhage. Other side effects may include intraventricular hemorrhage, patent ductus arteriosus, retinopathy, necrotizing enterocolitis, and/or blockage of the endotracheal tube can cause complications as well.
Contraindications to surfactant administration include congenital anomalies that are uncongenial with life, perfusion failure states, diffuse pulmonary hemorrhagic conditions, and a diagnosis of congenital diaphragmatic hernia. Contraindications also include neonates who display respiratory difficulty, but laboratory evidence suggests lung maturity has already occurred. Usage of surfactant appears to result in a deterioration in newborns with pulmonary hypoplasia, although more clinical trials-based evidence is needed.
Surfactant, especially being a drug administered to neonates, must be carefully monitored when given. Whether the drug administration is as a bolus or in aliquots, monitoring the endotracheal tubing for obstruction is just as essential as administering the drug itself. Because of the risks that accompany such procedures, it is vital to determine the definite necessity of this drug. Lung ultrasonography (LUS) scoring is a bedside technique useful to diagnose respiratory problems in neonates and has now become a tool to monitor lung function and guide surfactant therapy. The LUS score is an excellent indicator of oxygenation status. It thus can predict the need to administer surfactant in both term and pre-term babies (those with gestational ages of less than 34 weeks) on continuous positive airway pressure (CPAP). This approach is particularly useful in severe deficiency of surfactant; continuous positive airway pressure can fail, and such failure may pose a risk of lung injury.
Given that surfactant is a substance that is produced in the body and administered only when deficient, there have not been any serious reports of toxicities related to surfactant administration. The prerequisites for administration, namely the endotracheal intubation and CPAP usage, do possess some inherent risks, as mentioned above.
New advances in medicine are regularly assisting clinicians and their teams in their practice and enabling them to think creatively and make healthcare increasingly convenient for patients. Management of infants with respiratory distress syndrome is best with an interprofessional team. While the respiratory therapist may administer the surfactant, the NICU nurse (specifically neonate specialty-trained nurses), critical care specialist, and pulmonologist all have to be involved in the monitoring of the neonate. The volume, viscosity, and the mode of ventilation are all vital components for surfactant efficacy. After the administration of surfactant, the nurse has to monitor the vital signs and oxygenation. The respiratory therapist must monitor the ventilatory parameters at least for the first 60 minutes after surfactant administration.
The pharmacy will be responsible for ensuring proper preparation of the surfactant, verifying dosing and administration, and serving as a drug information resource to the rest of the team. Only with an interprofessional team approach and open communication can surfactant therapy optimally reduce the morbidity of respiratory distress syndrome in neonates. [Level 5]
Research has indicated that surfactant preparations have anti-inflammatory properties and can aid the immune system in cases of acute lung injury (ALI) secondary to LPS (lipopolysaccharide) endotoxin. Because the surfactant proteins play a role in regulating cytokine production by inflammatory cells, animal models have shown that they can effectively limit lung injury caused by LPS endotoxin. Additionally, new methods are persistently being tested and used to ease to delivery of surfactant and make the procedure less invasive, such as the LISA and MIST techniques mentioned above. These newer approaches improve patient safety and enhance team performances by improving care coordination. Not only that, but nanotechnology testing is also underway to determine whether surfactant may serve as a drug delivery system for the administration of alternative medications. Achievements in this regard are significantly enhancing the role of respiratory routes of drug administration using surfactant as a backbone.
|||Griese M, Pulmonary surfactant in health and human lung diseases: state of the art. The European respiratory journal. 1999 Jun; [PubMed PMID: 10445627]|
|||Polin RA,Carlo WA, Surfactant replacement therapy for preterm and term neonates with respiratory distress. Pediatrics. 2014 Jan; [PubMed PMID: 24379227]|
|||Walsh BK,Daigle B,DiBlasi RM,Restrepo RD, AARC Clinical Practice Guideline. Surfactant replacement therapy: 2013. Respiratory care. 2013 Feb [PubMed PMID: 23359726]|
|||Agassandian M,Mallampalli RK, Surfactant phospholipid metabolism. Biochimica et biophysica acta. 2013 Mar; [PubMed PMID: 23026158]|
|||Lawson PR,Reid KB, The roles of surfactant proteins A and D in innate immunity. Immunological reviews. 2000 Feb; [PubMed PMID: 10719668]|
|||Canals Candela FJ,Vizcaíno Díaz C,Ferrández Berenguer MJ,Serrano Robles MI,Vázquez Gomis C,Quiles Durá JL, [Surfactant replacement therapy with a minimally invasive technique: Experience in a tertiary hospital]. Anales de pediatria (Barcelona, Spain : 2003). 2016 Feb; [PubMed PMID: 26028565]|
|||Nouraeyan N,Lambrinakos-Raymond A,Leone M,Sant'Anna G, Surfactant administration in neonates: A review of delivery methods. Canadian journal of respiratory therapy : CJRT = Revue canadienne de la therapie respiratoire : RCTR. 2014 Fall; [PubMed PMID: 26078618]|
|||Kribs A, Minimally Invasive Surfactant Therapy and Noninvasive Respiratory Support. Clinics in perinatology. 2016 Dec; [PubMed PMID: 27837757]|
|||Aldana-Aguirre JC,Pinto M,Featherstone RM,Kumar M, Less invasive surfactant administration versus intubation for surfactant delivery in preterm infants with respiratory distress syndrome: a systematic review and meta-analysis. Archives of disease in childhood. Fetal and neonatal edition. 2017 Jan; [PubMed PMID: 27852668]|
|||Foglia EE,Jensen EA,Kirpalani H, Delivery room interventions to prevent bronchopulmonary dysplasia in extremely preterm infants. Journal of perinatology : official journal of the California Perinatal Association. 2017 Nov; [PubMed PMID: 28569744]|
|||APPELBAUM A, Retrolental fibroplasia; blindness in infants of low weight at birth. California medicine. 1952 Oct; [PubMed PMID: 13009470]|
|||Kalina RE, Treatment of retrolental fibroplasia. Survey of ophthalmology. 1980 Jan-Feb; [PubMed PMID: 6987763]|
|||Brat R,Yousef N,Klifa R,Reynaud S,Shankar Aguilera S,De Luca D, Lung Ultrasonography Score to Evaluate Oxygenation and Surfactant Need in Neonates Treated With Continuous Positive Airway Pressure. JAMA pediatrics. 2015 Aug; [PubMed PMID: 26237465]|
|||Kolomaznik M,Nova Z,Calkovska A, Pulmonary surfactant and bacterial lipopolysaccharide: the interaction and its functional consequences. Physiological research. 2017 Sep 22; [PubMed PMID: 28937231]|
|||Sweet DG,Carnielli V,Greisen G,Hallman M,Ozek E,Plavka R,Saugstad OD,Simeoni U,Speer CP,Vento M,Visser GH,Halliday HL, European Consensus Guidelines on the Management of Respiratory Distress Syndrome - 2016 Update. Neonatology. 2017; [PubMed PMID: 27649091]|
|||Hidalgo A,Cruz A,Pérez-Gil J, Pulmonary surfactant and nanocarriers: Toxicity versus combined nanomedical applications. Biochimica et biophysica acta. Biomembranes. 2017 Sep; [PubMed PMID: 28450046]|